JNCCN 360 – MM – FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma

By: Jocelyn Solis-Moreira, MS Posted: Thursday, August 6, 2020 On August 5, the U.S. Food and Drug Administration (FDA) approved the antibody drug-conjugate belantamab mafodotin-blmf (Blenrep) for treatment of adults with relapsed or refractory multiple myeloma. Drug eligibility includes patients who have had…

Read the full article here

Source: jnccn360.org
Categories: Hem/Onc News and Journals, Latest Headlines
Tags: , , ,
Tweets with this article
Journal of the @NCCN
FDA approves #belantamabmafodotinblmf for relapsed or refractory #myeloma: https://t.co/DdUoXf1R3U #MMSM #JNCCN360 https://t.co/50eHVlU1GU

Related Articles